Detection of EGFR Gene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay

Purpose: Mutations in the epidermal growth factor receptor ( EGFR ) gene have been reported to be present in non–small cell lung cancer (NSCLC) and related to the responsiveness of tumors to EGFR tyrosine kinase inhibitors, suggesting its usefulness as a biomarker. Because clinical samples contain t...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 12; no. 1; pp. 43 - 48
Main Authors ASANO, Hiroaki, TOYOOKA, Shinichi, HIRAKI, Akio, SUGI, Kazuro, KIURA, Katsuyuki, DATE, Hiroshi, SHIMIZU, Nobuyoshi, TOKUMO, Masaki, ICHIMURA, Kouichi, AOE, Keisuke, ITO, Sachio, TSUKUDA, Kazunori, OUCHIDA, Mamoru, AOE, Motoi, KATAYAMA, Hideki
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.01.2006
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose: Mutations in the epidermal growth factor receptor ( EGFR ) gene have been reported to be present in non–small cell lung cancer (NSCLC) and related to the responsiveness of tumors to EGFR tyrosine kinase inhibitors, suggesting its usefulness as a biomarker. Because clinical samples contain tumor and normal cells or genes, a highly sensitive assay for detecting mutation is critical for clinical applications. Experimental Design: The mutant-enriched PCR is a rapid and sensitive assay with selective restriction enzyme digestion. We developed the mutant-enriched PCR assay targeting exons 19 and 21 of EGFR and applied the developed assay to detect mutations in 108 cases of surgically resected specimens of NSCLCs, 18 samples of computed tomography (CT)–guided needle lung biopsies, and 20 samples of pleural fluid. In addition, results were then compared with those from direct sequencing and a nonenriched PCR assay. Results: The mutant-enriched PCR that was proved to enrich one mutant of 2 × 10 3 normal genes detected mutations in 37 cases of 108 resected tumors, seven samples of CT-guided lung biopsies, and seven samples of pleural fluid. Among mutant cases, four resected tumors, two CT-guided lung biopsies, and two pleural fluid were identified as additional mutant cases by the mutant-enriched PCR, which were considered normal based on nonenriched assays. Conclusions: Our results indicate that EGFR mutations are readily detectable by mutant-enriched PCR in various clinical samples. Thus, mutant-enriched PCR may provide a valuable method of potentially detecting a small fraction of mutant genes in heterogeneous specimens, indicating its possible use in clinical application for NSCLC.
AbstractList Mutations in the epidermal growth factor receptor (EGFR) gene have been reported to be present in non-small cell lung cancer (NSCLC) and related to the responsiveness of tumors to EGFR tyrosine kinase inhibitors, suggesting its usefulness as a biomarker. Because clinical samples contain tumor and normal cells or genes, a highly sensitive assay for detecting mutation is critical for clinical applications. The mutant-enriched PCR is a rapid and sensitive assay with selective restriction enzyme digestion. We developed the mutant-enriched PCR assay targeting exons 19 and 21 of EGFR and applied the developed assay to detect mutations in 108 cases of surgically resected specimens of NSCLCs, 18 samples of computed tomography (CT)-guided needle lung biopsies, and 20 samples of pleural fluid. In addition, results were then compared with those from direct sequencing and a nonenriched PCR assay. The mutant-enriched PCR that was proved to enrich one mutant of 2 x 10(3) normal genes detected mutations in 37 cases of 108 resected tumors, seven samples of CT-guided lung biopsies, and seven samples of pleural fluid. Among mutant cases, four resected tumors, two CT-guided lung biopsies, and two pleural fluid were identified as additional mutant cases by the mutant-enriched PCR, which were considered normal based on nonenriched assays. Our results indicate that EGFR mutations are readily detectable by mutant-enriched PCR in various clinical samples. Thus, mutant-enriched PCR may provide a valuable method of potentially detecting a small fraction of mutant genes in heterogeneous specimens, indicating its possible use in clinical application for NSCLC.
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene have been reported to be present in non-small cell lung cancer (NSCLC) and related to the responsiveness of tumors to EGFR tyrosine kinase inhibitors, suggesting its usefulness as a biomarker. Because clinical samples contain tumor and normal cells or genes, a highly sensitive assay for detecting mutation is critical for clinical applications. Experimental Design: The mutant-enriched PCR is a rapid and sensitive assay with selective restriction enzyme digestion. We developed the mutant-enriched PCR assay targeting exons 19 and 21 of EGFR and applied the developed assay to detect mutations in 108 cases of surgically resected specimens of NSCLCs, 18 samples of computed tomography (CT)-guided needle lung biopsies, and 20 samples of pleural fluid. In addition, results were then compared with those from direct sequencing and a nonenriched PCR assay. RESULTS: The mutant-enriched PCR that was proved to enrich one mutant of 2 x 10 super(3) normal genes detected mutations in 37 cases of 108 resected tumors, seven samples of CT-guided lung biopsies, and seven samples of pleural fluid. Among mutant cases, four resected tumors, two CT-guided lung biopsies, and two pleural fluid were identified as additional mutant cases by the mutant-enriched PCR, which were considered normal based on nonenriched assays. CONCLUSIONS: Our results indicate that EGFR mutations are readily detectable by mutant-enriched PCR in various clinical samples. Thus, mutant-enriched PCR may provide a valuable method of potentially detecting a small fraction of mutant genes in heterogeneous specimens, indicating its possible use in clinical application for NSCLC.
PURPOSEMutations in the epidermal growth factor receptor (EGFR) gene have been reported to be present in non-small cell lung cancer (NSCLC) and related to the responsiveness of tumors to EGFR tyrosine kinase inhibitors, suggesting its usefulness as a biomarker. Because clinical samples contain tumor and normal cells or genes, a highly sensitive assay for detecting mutation is critical for clinical applications.EXPERIMENTAL DESIGNThe mutant-enriched PCR is a rapid and sensitive assay with selective restriction enzyme digestion. We developed the mutant-enriched PCR assay targeting exons 19 and 21 of EGFR and applied the developed assay to detect mutations in 108 cases of surgically resected specimens of NSCLCs, 18 samples of computed tomography (CT)-guided needle lung biopsies, and 20 samples of pleural fluid. In addition, results were then compared with those from direct sequencing and a nonenriched PCR assay.RESULTSThe mutant-enriched PCR that was proved to enrich one mutant of 2 x 10(3) normal genes detected mutations in 37 cases of 108 resected tumors, seven samples of CT-guided lung biopsies, and seven samples of pleural fluid. Among mutant cases, four resected tumors, two CT-guided lung biopsies, and two pleural fluid were identified as additional mutant cases by the mutant-enriched PCR, which were considered normal based on nonenriched assays.CONCLUSIONSOur results indicate that EGFR mutations are readily detectable by mutant-enriched PCR in various clinical samples. Thus, mutant-enriched PCR may provide a valuable method of potentially detecting a small fraction of mutant genes in heterogeneous specimens, indicating its possible use in clinical application for NSCLC.
Purpose: Mutations in the epidermal growth factor receptor (EGFR) gene have been reported to be present in non–small cell lung cancer (NSCLC) and related to the responsiveness of tumors to EGFR tyrosine kinase inhibitors, suggesting its usefulness as a biomarker. Because clinical samples contain tumor and normal cells or genes, a highly sensitive assay for detecting mutation is critical for clinical applications. Experimental Design: The mutant-enriched PCR is a rapid and sensitive assay with selective restriction enzyme digestion. We developed the mutant-enriched PCR assay targeting exons 19 and 21 of EGFR and applied the developed assay to detect mutations in 108 cases of surgically resected specimens of NSCLCs, 18 samples of computed tomography (CT)–guided needle lung biopsies, and 20 samples of pleural fluid. In addition, results were then compared with those from direct sequencing and a nonenriched PCR assay. Results: The mutant-enriched PCR that was proved to enrich one mutant of 2 × 103 normal genes detected mutations in 37 cases of 108 resected tumors, seven samples of CT-guided lung biopsies, and seven samples of pleural fluid. Among mutant cases, four resected tumors, two CT-guided lung biopsies, and two pleural fluid were identified as additional mutant cases by the mutant-enriched PCR, which were considered normal based on nonenriched assays. Conclusions: Our results indicate that EGFR mutations are readily detectable by mutant-enriched PCR in various clinical samples. Thus, mutant-enriched PCR may provide a valuable method of potentially detecting a small fraction of mutant genes in heterogeneous specimens, indicating its possible use in clinical application for NSCLC.
Purpose: Mutations in the epidermal growth factor receptor ( EGFR ) gene have been reported to be present in non–small cell lung cancer (NSCLC) and related to the responsiveness of tumors to EGFR tyrosine kinase inhibitors, suggesting its usefulness as a biomarker. Because clinical samples contain tumor and normal cells or genes, a highly sensitive assay for detecting mutation is critical for clinical applications. Experimental Design: The mutant-enriched PCR is a rapid and sensitive assay with selective restriction enzyme digestion. We developed the mutant-enriched PCR assay targeting exons 19 and 21 of EGFR and applied the developed assay to detect mutations in 108 cases of surgically resected specimens of NSCLCs, 18 samples of computed tomography (CT)–guided needle lung biopsies, and 20 samples of pleural fluid. In addition, results were then compared with those from direct sequencing and a nonenriched PCR assay. Results: The mutant-enriched PCR that was proved to enrich one mutant of 2 × 10 3 normal genes detected mutations in 37 cases of 108 resected tumors, seven samples of CT-guided lung biopsies, and seven samples of pleural fluid. Among mutant cases, four resected tumors, two CT-guided lung biopsies, and two pleural fluid were identified as additional mutant cases by the mutant-enriched PCR, which were considered normal based on nonenriched assays. Conclusions: Our results indicate that EGFR mutations are readily detectable by mutant-enriched PCR in various clinical samples. Thus, mutant-enriched PCR may provide a valuable method of potentially detecting a small fraction of mutant genes in heterogeneous specimens, indicating its possible use in clinical application for NSCLC.
Author Keisuke Aoe
Kazuro Sugi
Akio Hiraki
Nobuyoshi Shimizu
Motoi Aoe
Shinichi Toyooka
Mamoru Ouchida
Masaki Tokumo
Sachio Ito
Kazunori Tsukuda
Kouichi Ichimura
Hideki Katayama
Hiroaki Asano
Katsuyuki Kiura
Hiroshi Date
Author_xml – sequence: 1
  givenname: Hiroaki
  surname: ASANO
  fullname: ASANO, Hiroaki
  organization: Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 2
  givenname: Shinichi
  surname: TOYOOKA
  fullname: TOYOOKA, Shinichi
  organization: Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 3
  givenname: Akio
  surname: HIRAKI
  fullname: HIRAKI, Akio
  organization: Department of Hematology, Oncology, and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 4
  givenname: Kazuro
  surname: SUGI
  fullname: SUGI, Kazuro
  organization: NHO Sanyo National Hospital Respiratory Disease Center, Ube, Yamaguchi, Japan
– sequence: 5
  givenname: Katsuyuki
  surname: KIURA
  fullname: KIURA, Katsuyuki
  organization: Department of Hematology, Oncology, and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 6
  givenname: Hiroshi
  surname: DATE
  fullname: DATE, Hiroshi
  organization: Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 7
  givenname: Nobuyoshi
  surname: SHIMIZU
  fullname: SHIMIZU, Nobuyoshi
  organization: Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 8
  givenname: Masaki
  surname: TOKUMO
  fullname: TOKUMO, Masaki
  organization: Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 9
  givenname: Kouichi
  surname: ICHIMURA
  fullname: ICHIMURA, Kouichi
  organization: Department of Pathology, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 10
  givenname: Keisuke
  surname: AOE
  fullname: AOE, Keisuke
  organization: NHO Sanyo National Hospital Respiratory Disease Center, Ube, Yamaguchi, Japan
– sequence: 11
  givenname: Sachio
  surname: ITO
  fullname: ITO, Sachio
  organization: Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 12
  givenname: Kazunori
  surname: TSUKUDA
  fullname: TSUKUDA, Kazunori
  organization: Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 13
  givenname: Mamoru
  surname: OUCHIDA
  fullname: OUCHIDA, Mamoru
  organization: Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 14
  givenname: Motoi
  surname: AOE
  fullname: AOE, Motoi
  organization: Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
– sequence: 15
  givenname: Hideki
  surname: KATAYAMA
  fullname: KATAYAMA, Hideki
  organization: NHO Sanyo National Hospital Respiratory Disease Center, Ube, Yamaguchi, Japan
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17515608$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16397022$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1v1DAQhi1U1I-lPwGUC9xSPP6Kc6zCdqm0iGpVzpbjTJqgrFPsRGj_Pd4PtMeebHmeGY-e94Zc-NEjIR-B3gFI_RVooXMqOLurqk1OZU5LLt6Ra5CyyDlT8iLd_zNX5CbG35SCACouyRUoXhaUsWtiv-GEbupHn41ttlw9bLIVesx-zJM9vPY-W8_-Jausdxiyenco-Slf-tC7DpvsaRx2Www2YlZ1NvEbtMeJ9zHa3QfyvrVDxNvTuSC_HpbP1fd8_XP1WN2vc8fLcsp5SZu0IC1Zwyir61ZoVkOLtm61ThUUkpV1w0ELUJaB00xoK5yjwJmkLV-QL8e5r2H8M2OczLaPDofBehznaFShaMG1ehOEQiglk84FkUfQhTHGgK15Df3Whp0BavYhmL1gsxdsUgiGSrMPIfV9On0w11tszl0n6wn4fAJsdHZoQ3LbxzNXSJCK6vOmXf_S_e0DGndIIWBEG1xngBkwgvN_gxOc2Q
CitedBy_id crossref_primary_10_1097_JTO_0b013e318206a221
crossref_primary_10_1016_j_aca_2022_340167
crossref_primary_10_1371_journal_pone_0081975
crossref_primary_10_1111_j_1349_7006_2006_00216_x
crossref_primary_10_1378_chest_06_1673
crossref_primary_10_3892_mco_2015_690
crossref_primary_10_1016_j_lungcan_2008_06_021
crossref_primary_10_1593_neo_101744
crossref_primary_10_1002_cncy_21835
crossref_primary_10_1039_C5AN01270H
crossref_primary_10_1002_cncy_21322
crossref_primary_10_1158_0008_5472_CAN_06_1951
crossref_primary_10_1039_C5RA26225A
crossref_primary_10_1097_JTO_0b013e318189f579
crossref_primary_10_1111_j_1349_7006_2009_01273_x
crossref_primary_10_1158_1078_0432_CCR_06_0658
crossref_primary_10_3346_jkms_2016_31_8_1224
crossref_primary_10_1007_s00280_010_1325_x
crossref_primary_10_1016_j_bios_2014_06_037
crossref_primary_10_1016_j_cca_2008_11_018
crossref_primary_10_1111_1759_7714_13014
crossref_primary_10_1007_s13665_013_0041_5
crossref_primary_10_1016_j_lungcan_2012_09_006
crossref_primary_10_1016_j_lungcan_2010_10_014
crossref_primary_10_1016_j_humpath_2015_08_010
crossref_primary_10_1007_s12253_014_9778_6
crossref_primary_10_1016_j_lungcan_2007_10_011
crossref_primary_10_1097_PAP_0b013e31817bf5a9
crossref_primary_10_1093_qjmed_hcv103
crossref_primary_10_1590_S1806_37132015000004531
crossref_primary_10_5649_jjphcs_35_468
crossref_primary_10_1016_j_foodcont_2020_107088
crossref_primary_10_1016_j_lungcan_2011_02_015
crossref_primary_10_1039_C5AN01863C
crossref_primary_10_1097_JTO_0b013e31829f691f
crossref_primary_10_15829_1728_8800_2021_3114
crossref_primary_10_1111_resp_13463
crossref_primary_10_1016_j_jmoldx_2017_05_007
crossref_primary_10_1200_JCO_2007_12_9858
crossref_primary_10_2353_jmoldx_2010_090140
crossref_primary_10_47429_lmo_2022_12_4_235
crossref_primary_10_1016_j_bios_2006_11_018
crossref_primary_10_1097_JTO_0000000000000130
crossref_primary_10_3892_ol_2011_471
crossref_primary_10_1371_journal_pone_0007464
crossref_primary_10_1016_j_lungcan_2011_05_015
crossref_primary_10_3892_ol_2018_8844
crossref_primary_10_1158_1078_0432_CCR_07_5207
crossref_primary_10_1038_modpathol_3801018
crossref_primary_10_3892_or_2014_3197
crossref_primary_10_1177_147323001103900425
crossref_primary_10_1016_j_ejmech_2020_112691
crossref_primary_10_1016_j_cllc_2012_01_008
crossref_primary_10_1186_2049_6958_7_52
crossref_primary_10_1016_j_lungcan_2007_01_014
crossref_primary_10_3892_or_2012_2087
crossref_primary_10_1097_JTO_0b013e31816de2cd
crossref_primary_10_1039_C8LC01193A
crossref_primary_10_1136_jclinpath_2011_200275
crossref_primary_10_1097_JTO_0b013e3181e59a7b
crossref_primary_10_17546_msd_569279
crossref_primary_10_1016_j_bios_2015_07_043
crossref_primary_10_1038_sj_bjc_6603428
crossref_primary_10_1039_C6AN02526A
crossref_primary_10_1097_JTO_0b013e3181654423
crossref_primary_10_1097_JTO_0b013e318168d20a
crossref_primary_10_1097_JTO_0b013e31818071f3
crossref_primary_10_1515_cclm_2017_0112
crossref_primary_10_1016_j_ab_2016_09_002
crossref_primary_10_1158_1078_0432_CCR_07_4921
crossref_primary_10_1371_journal_pone_0019601
crossref_primary_10_1097_PDM_0000000000000037
crossref_primary_10_1373_clinchem_2017_278911
crossref_primary_10_1016_j_lungcan_2012_04_003
crossref_primary_10_1097_PDM_0000000000000035
crossref_primary_10_1016_j_snb_2018_12_060
crossref_primary_10_1021_acsabm_9b01218
crossref_primary_10_1002_ijc_24653
crossref_primary_10_1007_s00330_021_08366_y
crossref_primary_10_1097_JTO_0b013e318186fadd
crossref_primary_10_6058_jlc_2012_11_2_77
crossref_primary_10_1111_j_1440_1843_2010_01746_x
crossref_primary_10_1002_ijc_22190
crossref_primary_10_1007_BF03256471
crossref_primary_10_1007_s13277_014_2643_0
crossref_primary_10_1016_j_yexmp_2013_12_006
crossref_primary_10_2353_jmoldx_2010_090208
crossref_primary_10_1158_1078_0432_CCR_07_1387
crossref_primary_10_4993_acrt_20_01
crossref_primary_10_1097_JTO_0b013e31817c6080
crossref_primary_10_1007_s00280_006_0312_8
crossref_primary_10_1002_ijc_22513
crossref_primary_10_1002_cncy_20150
crossref_primary_10_3892_ijo_2018_4334
crossref_primary_10_1158_0008_5472_CAN_12_4136
crossref_primary_10_3892_ijo_2015_2875
crossref_primary_10_1039_C4RA10181B
crossref_primary_10_1186_1756_9966_32_50
crossref_primary_10_1097_PCR_0b013e3181b9a867
crossref_primary_10_1016_j_ab_2009_11_034
crossref_primary_10_1007_s12253_016_0063_8
crossref_primary_10_1158_1078_0432_CCR_07_0627
crossref_primary_10_1158_1078_0432_CCR_07_0509
crossref_primary_10_15324_kjcls_2015_47_3_125
crossref_primary_10_1097_JTO_0b013e31823c4c1b
crossref_primary_10_1016_j_gene_2017_10_023
crossref_primary_10_1097_CCO_0b013e328012d5fa
crossref_primary_10_1186_1477_7819_11_266
crossref_primary_10_3390_ijms17050792
crossref_primary_10_1007_s12253_014_9874_7
crossref_primary_10_1080_14737140_2018_1508347
crossref_primary_10_1186_s43046_022_00139_y
crossref_primary_10_1016_j_clinbiochem_2014_08_015
crossref_primary_10_1038_s41551_017_0058
crossref_primary_10_1016_j_jmoldx_2013_06_006
crossref_primary_10_1158_1078_0432_CCR_08_2622
crossref_primary_10_1038_s41467_022_34627_5
crossref_primary_10_1007_s10147_008_0772_4
crossref_primary_10_1016_j_ejmech_2022_114100
crossref_primary_10_1111_j_1440_1827_2011_02679_x
crossref_primary_10_1371_journal_pone_0163652
crossref_primary_10_2169_internalmedicine_46_6204
crossref_primary_10_3892_ol_2015_3652
crossref_primary_10_1002_ijc_24150
crossref_primary_10_1136_jclinpath_2012_201194
crossref_primary_10_1016_j_ab_2012_06_018
crossref_primary_10_1007_s11739_007_0002_5
crossref_primary_10_1002_ijc_22818
crossref_primary_10_1016_j_cca_2014_01_049
crossref_primary_10_1038_modpathol_2011_184
crossref_primary_10_5858_arpa_2012_0263_RA
crossref_primary_10_1586_14737159_7_6_821
crossref_primary_10_1378_chest_07_0095
crossref_primary_10_1007_BF03257190
crossref_primary_10_7314_APJCP_2014_15_11_4493
crossref_primary_10_1002_ijc_23868
crossref_primary_10_5795_jjscc_51_341
crossref_primary_10_1016_S0761_8425_07_91669_1
crossref_primary_10_1007_s00216_023_04743_2
crossref_primary_10_1007_s10585_013_9603_8
crossref_primary_10_1007_s11307_020_01487_8
crossref_primary_10_2353_jmoldx_2008_070125
crossref_primary_10_1016_j_lungcan_2008_12_001
crossref_primary_10_1007_s11523_007_0053_6
crossref_primary_10_1111_jcmm_13007
crossref_primary_10_1089_gtmb_2015_0069
crossref_primary_10_1245_s10434_011_1942_6
crossref_primary_10_5858_2011_0029_RAI_1
crossref_primary_10_1016_j_cllc_2013_04_005
crossref_primary_10_1097_JTO_0b013e3181a94af4
crossref_primary_10_1016_j_sasc_2024_200110
crossref_primary_10_1016_j_lungcan_2007_04_007
crossref_primary_10_1097_PAS_0b013e31815cb162
Cites_doi 10.1200/JCO.1999.17.2.578
10.1016/0003-2697(91)90293-3
10.1158/1078-0432.CCR-04-1245
10.1073/pnas.0405220101
10.1002/1097-0142(20000825)90:4<258::AID-CNCR10>3.0.CO;2-F
10.1378/chest.125.5_suppl.97S-a
10.1158/1078-0432.1167.11.3
10.1093/jnci/dji055
10.3892/or.10.5.1455
10.1056/NEJMoa040938
10.1016/S1470-2045(01)00486-7
10.1126/science.1099314
10.1200/JCO.2003.10.038
10.1002/(SICI)1097-0215(19960503)66:3<332::AID-IJC11>3.0.CO;2-D
10.1200/JCO.2003.11.069
10.1136/gut.52.1.101
10.1183/09031936.02.00062002
10.1158/0008-5472.CAN-04-2818
ContentType Journal Article
Copyright 2006 INIST-CNRS
Copyright_xml – notice: 2006 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TO
8FD
FR3
H94
P64
RC3
7X8
DOI 10.1158/1078-0432.CCR-05-0934
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Oncogenes and Growth Factors Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
Genetics Abstracts
Engineering Research Database
Oncogenes and Growth Factors Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
AIDS and Cancer Research Abstracts
MEDLINE - Academic
CrossRef

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 48
ExternalDocumentID 10_1158_1078_0432_CCR_05_0934
16397022
17515608
12_1_43
Genre Journal Article
Comparative Study
GroupedDBID -
08R
29B
2WC
34G
39C
3O-
4H-
53G
55
5GY
5RE
5VS
AAPBV
ABFLS
ABOCM
ACIWK
ACPRK
ADACO
ADBBV
ADBIT
AENEX
AETEA
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FH7
FRP
GJ
GX1
H13
H~9
IH2
KQ8
L7B
LSO
MVM
O0-
OHT
OK1
P0W
P2P
RCR
RHF
RHI
RNS
SJN
UDS
VH1
W2D
WOQ
X7M
XFK
XJT
ZA5
ZCG
ZGI
---
.55
.GJ
18M
1CY
2FS
476
6J9
AAUGY
ACGFO
ACSVP
ADCOW
ADNWM
AFHIN
AFOSN
AI.
BR6
BTFSW
IQODW
J5H
QTD
TR2
W8F
WHG
YKV
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TO
8FD
FR3
H94
P64
RC3
7X8
ID FETCH-LOGICAL-c399t-390d001092d202bbf482b1feabf88d00e4529bd318416a21c8248a4cc013250f3
ISSN 1078-0432
IngestDate Fri Oct 25 02:41:58 EDT 2024
Thu Sep 26 11:54:51 EDT 2024
Thu Nov 21 21:02:40 EST 2024
Sat Sep 28 07:52:49 EDT 2024
Sun Oct 29 17:10:16 EDT 2023
Fri Jan 15 20:06:55 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Lung disease
Respiratory disease
Lung cancer
Malignant tumor
Bronchopulmonary
Epidermal growth factor receptor
Polymerase chain reaction
Gene
Bronchus disease
Genetics
Diagnosis
Mutation
Molecular biology
Detection
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c399t-390d001092d202bbf482b1feabf88d00e4529bd318416a21c8248a4cc013250f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 16397022
PQID 17466509
PQPubID 23462
PageCount 6
ParticipantIDs proquest_miscellaneous_67607386
proquest_miscellaneous_17466509
crossref_primary_10_1158_1078_0432_CCR_05_0934
pubmed_primary_16397022
pascalfrancis_primary_17515608
highwire_cancerresearch_12_1_43
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 20060101
2006
2006-Jan-01
2006-01-01
PublicationDateYYYYMMDD 2006-01-01
PublicationDate_xml – month: 01
  year: 2006
  text: 20060101
  day: 01
PublicationDecade 2000
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
– name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2006
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
References 2022061104335708800_B20
2022061104335708800_B9
2022061104335708800_B11
2022061104335708800_B10
2022061104335708800_B13
2022061104335708800_B12
2022061104335708800_B15
2022061104335708800_B14
2022061104335708800_B17
2022061104335708800_B16
2022061104335708800_B1
2022061104335708800_B19
2022061104335708800_B2
2022061104335708800_B18
2022061104335708800_B3
2022061104335708800_B4
2022061104335708800_B5
2022061104335708800_B6
2022061104335708800_B7
2022061104335708800_B8
References_xml – ident: 2022061104335708800_B12
  doi: 10.1200/JCO.1999.17.2.578
– ident: 2022061104335708800_B17
  doi: 10.1016/0003-2697(91)90293-3
– ident: 2022061104335708800_B20
– ident: 2022061104335708800_B9
  doi: 10.1158/1078-0432.CCR-04-1245
– ident: 2022061104335708800_B7
  doi: 10.1073/pnas.0405220101
– ident: 2022061104335708800_B13
  doi: 10.1002/1097-0142(20000825)90:4<258::AID-CNCR10>3.0.CO;2-F
– ident: 2022061104335708800_B3
  doi: 10.1378/chest.125.5_suppl.97S-a
– ident: 2022061104335708800_B10
  doi: 10.1158/1078-0432.1167.11.3
– ident: 2022061104335708800_B11
  doi: 10.1093/jnci/dji055
– ident: 2022061104335708800_B18
  doi: 10.3892/or.10.5.1455
– ident: 2022061104335708800_B5
  doi: 10.1056/NEJMoa040938
– ident: 2022061104335708800_B1
  doi: 10.1016/S1470-2045(01)00486-7
– ident: 2022061104335708800_B6
  doi: 10.1126/science.1099314
– ident: 2022061104335708800_B4
  doi: 10.1200/JCO.2003.10.038
– ident: 2022061104335708800_B15
  doi: 10.1002/(SICI)1097-0215(19960503)66:3<332::AID-IJC11>3.0.CO;2-D
– ident: 2022061104335708800_B16
– ident: 2022061104335708800_B19
  doi: 10.1200/JCO.2003.11.069
– ident: 2022061104335708800_B14
  doi: 10.1136/gut.52.1.101
– ident: 2022061104335708800_B2
  doi: 10.1183/09031936.02.00062002
– ident: 2022061104335708800_B8
  doi: 10.1158/0008-5472.CAN-04-2818
SSID ssj0014104
Score 2.3327422
Snippet Purpose: Mutations in the epidermal growth factor receptor ( EGFR ) gene have been reported to be present in non–small cell lung cancer (NSCLC) and related to...
Mutations in the epidermal growth factor receptor (EGFR) gene have been reported to be present in non-small cell lung cancer (NSCLC) and related to the...
Purpose: Mutations in the epidermal growth factor receptor (EGFR) gene have been reported to be present in non–small cell lung cancer (NSCLC) and related to...
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene have been reported to be present in non-small cell lung cancer (NSCLC) and related to...
PURPOSEMutations in the epidermal growth factor receptor (EGFR) gene have been reported to be present in non-small cell lung cancer (NSCLC) and related to the...
SourceID proquest
crossref
pubmed
pascalfrancis
highwire
SourceType Aggregation Database
Index Database
Publisher
StartPage 43
SubjectTerms Antineoplastic agents
Biological and medical sciences
Biopsy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
CT-guided needle lung biopsy
DNA Mutational Analysis
DNA Primers
EGFR
Female
Genes, erbB-1 - genetics
Humans
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Medical sciences
mutant-enriched PCR
Mutation
NSCLC
Pharmacology. Drug treatments
Pleural Effusion
pleural fluid
Pneumology
Polymerase Chain Reaction - methods
Sensitivity and Specificity
Tumors of the respiratory system and mediastinum
Title Detection of EGFR Gene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay
URI http://clincancerres.aacrjournals.org/content/12/1/43.abstract
https://www.ncbi.nlm.nih.gov/pubmed/16397022
https://search.proquest.com/docview/17466509
https://search.proquest.com/docview/67607386
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXcFCh6CbrXXVIeegvkaqFk-Wi4SewaiQE3BtITQUokbLSVA1s6JD_VX-wMScl2FnS5CIYoDCXO83A4KyEfRR4p2OaZxxKmPRbnXU8GUeCJLrYXwXrpEhOFT8-S4Yx9uYgvWq1fW1FLVSk72fWdeSX_w1W4B3zFLNl_4GxDFG7Ab-AvXIHDcP0rHn9Wpcpqle_o5HiKDZHV4c_KhRAuisMfFSbVImtXqGniUFF6QBBDQHPs0XCFZikMWp8Lk9tSNw9fr8WOy3dQ51A6aq5MUGNO7n_tn03MTrZYLUEvbWwCk2-TybhvzKxzJDFvhoajaX88MuLpu40HM8ae2cnIBnpcV6vlrlliA6Ha07SFLxMyObBvN91-Oyt0fazyy5ydUzlBHIPwC20fiUZSh7cQacWurfTkNnBbufP21hCnxkrh5uoMBlMTuNhzxtSdUtw3tsgmcBGULUw9Tx-Qh6byImrho3HjtmKB6VfZTOJSxmDqT3dOvKsM1QWqMT5XrIGh2vZWuf_wY5Sg8ydk351eaN9C8SlpqeIZeXTq4jOeE9Egki41RURSRCStEUkXBUVEUoshKq_oDUTSDSKpQSStEUkNIl-Q2fHR-WDouSYeXga6b-lFPT83_tcwD_1QSs3SUAZaCanTFEYUev5lDlsLHA1EGGRpyFLBsgydgLGvo5dkr1gW6jWhys-CSDGtQU1mcVeIXpJGXS3hFA1qv9Zt0qlXk1_aWi3cnHHjlOPyc1x-DsvP_Zjj8rfJh3rNuf3u-q_Dg5AHnEVtcrDDig1dBwQgUfOGg2BGb5so1LJawxMswfKU9z-RdBMfe-62ySvL1A11dLeDdv3mT9O_JY83NsF3ZK9cVeo9aMmlPDDI_A2hRrrW
link.rule.ids 314,780,784,4024,27923,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Detection+of+EGFR+gene+mutation+in+lung+cancer+by+mutant-enriched+polymerase+chain+reaction+assay&rft.jtitle=Clinical+cancer+research&rft.au=ASANO%2C+Hiroaki&rft.au=TOYOOKA%2C+Shinichi&rft.au=HIRAKI%2C+Akio&rft.au=SUGI%2C+Kazuro&rft.date=2006&rft.pub=American+Association+for+Cancer+Research&rft.issn=1078-0432&rft.eissn=1557-3265&rft.volume=12&rft.issue=1&rft.spage=43&rft.epage=48&rft_id=info:doi/10.1158%2F1078-0432.CCR-05-0934&rft.externalDBID=n%2Fa&rft.externalDocID=17515608
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon